BBNX

SAN DIEGO, July 1, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its second quarter 2026 financial results after the financial markets close on Wednesday, July 29, 2026.

SAN DIEGO, June 29, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

SAN DIEGO, June 22, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

SAN DIEGO, June 17, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

SAN DIEGO, June 12, 2026 /PRNewswire/ -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

San Diego, California--(Newsfile Corp. - June 9, 2026) - Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Beta Bionics, Inc. (NASDAQ: BBNX). The investigation concerns whether Beta Bionics or certain of its executive officers made false or misleading statements, or failed to disclose material information, concerning the Company's growth trends, new patient starts, business outlook, and related operating metrics.

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Beta Bionics, Inc. (NASDAQ: BBNX) or certain of its executive officers violated federal securities laws.